Form 4: Mirum Pharmaceuticals Director Patrick J. Heron Acquires Stock Options and Restricted Stock Units

Director Patrick J. Heron acquired stock options and restricted stock units in Mirum Pharmaceuticals, Inc. on June 5, 2024, according to a Form 4 filing.

Summary

• On June 5, 2024, Patrick J. Heron, a director of Mirum Pharmaceuticals, Inc., acquired 8,779 stock options with an exercise price of $26.30.
• These options vest on the first anniversary of the grant date but will be fully vested by the company's 2025 annual stockholder meeting.
• Heron also acquired 5,703 restricted stock units (RSUs), each representing a contingent right to receive one share of Mirum's common stock.
• These RSUs also vest on the first anniversary of the grant date and will be fully vested by the 2025 annual stockholder meeting.
• Following these transactions, Heron directly owns 8,779 shares of common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of stock options and RSUs can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedules for the stock options and RSUs indicate a long-term incentive structure tied to the company's performance leading up to the 2025 annual stockholder meeting.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. These filings are closely watched by investors for insights into management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates